Suppr超能文献

载脂蛋白 A-I 模拟肽的结构/功能关系:对高密度脂蛋白抗动脉粥样硬化活性的影响。

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

机构信息

Baker Heart and Diabetes Institute, PO Box 6492, St Kilda Rd, Melbourne 8008, Australia.

出版信息

Circ Res. 2010 Jul 23;107(2):217-27. doi: 10.1161/CIRCRESAHA.110.216507. Epub 2010 May 27.

Abstract

RATIONALE

Apolipoprotein (apoA)-I mimetic peptides are a promising type of anti-atherosclerosis therapy, but how the structural features of these peptides relate to the multiple antiatherogenic functions of HDL is poorly understood.

OBJECTIVE

To establish structure/function relationships of apoA-I mimetic peptides with their antiatherogenic functions.

METHODS AND RESULTS

Twenty-two bihelical apoA-I mimetic peptides were investigated in vitro for the capacity and specificity of cholesterol efflux, inhibition of inflammatory response of monocytes and endothelial cells, and inhibition of low-density lipoprotein (LDL) oxidation. It was found that mean hydrophobicity, charge, size of hydrophobic face, and angle of the link between the helices are the major factors determining the efficiency and specificity of cholesterol efflux. The peptide with optimal parameters was more effective and specific toward cholesterol efflux than human apoA-I. Charge and size of hydrophobic face were also the major factors affecting antiinflammatory properties, and the presence of cysteine and histidine residues was the main factor determining antioxidant properties. There was no significant correlation between capacities of the peptides to support individual functions; each function had its own optimal set of features.

CONCLUSIONS

None of the peptides was equally effective in all the antiatherogenic functions tested, suggesting that different functions of HDL may have different mechanisms and different structural requirements. The results do suggest, however, that rationalizing the design of apoA-I mimetic peptides may improve their therapeutic value and may lead to a better understanding of mechanisms of various antiatherogenic functions of HDL.

摘要

理由

载脂蛋白(apoA)-I 模拟肽是一种很有前途的抗动脉粥样硬化治疗方法,但这些肽的结构特征与高密度脂蛋白(HDL)的多种抗动脉粥样硬化功能之间的关系还知之甚少。

目的

建立载脂蛋白 A-I 模拟肽的结构/功能关系与其抗动脉粥样硬化功能。

方法和结果

在体外研究了 22 种双螺旋载脂蛋白 A-I 模拟肽,以评估其胆固醇外排能力和特异性、抑制单核细胞和内皮细胞炎症反应以及抑制低密度脂蛋白(LDL)氧化的能力。结果发现,平均疏水性、电荷、疏水面大小以及螺旋之间连接的角度是决定胆固醇外排效率和特异性的主要因素。具有最佳参数的肽比人载脂蛋白 A-I 更有效和特异性地进行胆固醇外排。电荷和疏水面大小也是影响抗炎特性的主要因素,而半胱氨酸和组氨酸残基的存在是决定抗氧化特性的主要因素。肽支持各个功能的能力之间没有显著相关性;每种功能都有其最佳的特征集。

结论

在所测试的所有抗动脉粥样硬化功能中,没有一种肽是同样有效的,这表明 HDL 的不同功能可能具有不同的机制和不同的结构要求。然而,结果确实表明,合理化载脂蛋白 A-I 模拟肽的设计可以提高其治疗价值,并可能有助于更好地理解 HDL 的各种抗动脉粥样硬化功能的机制。

相似文献

5
High-density lipoprotein reduces the human monocyte inflammatory response.高密度脂蛋白可降低人类单核细胞的炎症反应。
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7. doi: 10.1161/ATVBAHA.108.168690. Epub 2008 Jul 10.

引用本文的文献

3
Anti-inflammatory mechanism of Apolipoprotein A-I.载脂蛋白 A-I 的抗炎机制。
Front Immunol. 2024 Jul 8;15:1417270. doi: 10.3389/fimmu.2024.1417270. eCollection 2024.
5
Inhibition of Vascular Inflammation by Apolipoprotein A-IV.载脂蛋白A-IV对血管炎症的抑制作用。
Front Cardiovasc Med. 2022 Jun 30;9:901408. doi: 10.3389/fcvm.2022.901408. eCollection 2022.
8
HDL and type 2 diabetes: the chicken or the egg?高密度脂蛋白与2型糖尿病:先有鸡还是先有蛋?
Diabetologia. 2021 Sep;64(9):1917-1926. doi: 10.1007/s00125-021-05509-0. Epub 2021 Jul 13.

本文引用的文献

9
High-density lipoprotein reduces the human monocyte inflammatory response.高密度脂蛋白可降低人类单核细胞的炎症反应。
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7. doi: 10.1161/ATVBAHA.108.168690. Epub 2008 Jul 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验